European Pharmaceutical Review

JULY 17, 2023

billion for phased clinical trials of US Food and Drug Administration (FDA)-approved drugs between 2010-2019. million publications describing basic or applied research related to 386 of 387 drugs approved 2010-2019 with $8.1 million per approved drug. billion (3.3 Average NIH spending was $33.8

Food and Drug Administration 98

Food and Drug Administration Training Pharmaceutical Food 98

Pharmaceutical Technology

JUNE 29, 2022

The US Food and Drug Administration (FDA) put a high-profile bluebird bio trial for sickle cell disease on partial clinical hold, and advisory panels deliberated over decisions involving gene therapies for amyotrophic lateral sclerosis (ALS), cerebral adrenoleukodystrophy (CALD), and beta-thalassemia.

Food and Drug Administration 98

Food and Drug Administration Marketing FDA Pharmaceutical 98

PM360

OCTOBER 28, 2022

Shepherding a new drug to market is a long, expensive, and uncertain process. billion dollars to bring a new drug from discovery to regulatory approval and market launch. Approval success rates of drug candidates are between 10%–20% in the United States, the European Union, and Japan. in 2010 to only 1.9%

Pharma 105

Pharma Food and Drug Administration Medicine Government 105

Pharmaceutical Technology

MAY 17, 2023

To ensure wide access to eligible patients, we are excited to partner with the IDEOGEN Group, a company focused on the commercialisation of speciality medicines for rare diseases across Europe.” In 2010, the US Food and Drug Administration approved Glassia for the same indication.

Marketing 52

Marketing Food and Drug Administration Specialization Food 52

Pharmaceutical Technology

APRIL 27, 2023

The CHMP used evidence from a Phase III trial ( NCT03729362 ) involving 123 patients with late-onset Pompe Disease (LOPD) to adopt a positive opinion for Opfolda. Sanofi markets avalglucosidase alfa as Lumizyme in the US to treat LOPD since its approval in 2010. A decision from the European Commission (EC) is expected in Q3 2023.

Food and Drug Administration 52

Food and Drug Administration Food Marketing Medicine 52

Clarivate

MAY 24, 2022

Recent policy and regulatory moves have begun to sketch out a framework for rare disease drug approvals in the country, but obstacles to approvals and patient access remain. Mainland China has taken significant steps toward improving access to treatment for its estimated 20 million rare disease patients in recent years. [1]

Patients 52

Patients Food and Drug Administration Marketing Pharma 52

Pharmaceutical Technology

MAY 18, 2023

Add in complex trial protocols, and many participants have reported feeling a lack of patient engagement and support [i]. Other processes include direct-to-patient (DtP) shipments of drugs and other supplies to a patient’s home, as well as in-home care with mobile nurses. of all terminated trials.

Recruitment 52

Recruitment Food and Drug Administration Patients Media 52